Ampyra Trial Failure Is Not All Bad News For Acorda
This article was originally published in The Pink Sheet Daily
Executive Summary
Lower dose of Acorda’s MS drug Ampyra fails to meet primary endpoint in new study, reassuring investors on the IP front. But the higher, approved dose also missed the mark, which raises questions about a negative commercial impact.